一分钟看懂
这是一项关于尿路上皮癌的II 期研究，登记的药物或干预包括Enfortumab vedotin；Pembrolizumab，当前状态为尚未开始招募。登记地点显示中国Salt Lake City有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Enfortumab vedotin；Pembrolizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Huntsman Cancer Institute at University of Utah · Salt Lake City
公开的入选条件
- * Participant aged ≥ 18 years.
- * Disease criteria:
- Histologically confirmed muscle-invasive urothelial carcinoma (T2-T3N0M0) without small cell variant histology of bladder. Other variant histologies are allowed if urothelial histology is present.
- No evidence of local or distant metastasis on CT scans.
- Urothelial carcinomas not originating from the bladder (eg, upper tract \[ureters, renal pelvis\], urethra) are not eligible.
- * Eligible to receive enfortumab vedotin and pembrolizumab.
- * ECOG Performance Status ≤ 2.
- * Adequate organ function as defined as:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07822373；登记信息更新于 2026-09-16。